Ferring
Ferring Pharmaceuticals, a global biopharmaceutical company headquartered in India, has established itself as a leader in reproductive health, urology, and gastroenterology since its founding in 1950. With a strong presence in Europe, North America, and Asia, Ferring is dedicated to developing innovative therapies that address unmet medical needs. The company is renowned for its core products, including hormone therapies and treatments for various gastrointestinal disorders, which are distinguished by their patient-centric approach and commitment to research and development. Ferring's notable achievements include pioneering advancements in assisted reproductive technology, solidifying its market position as a trusted provider of specialised healthcare solutions. Through its dedication to science and patient care, Ferring continues to make significant contributions to the biopharmaceutical industry.
DitchCarbon Score
How does Ferring's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ferring's score of 30 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ferring's reported carbon emissions
In 2023, Ferring reported total carbon emissions of approximately 580,198,000 kg CO2e, which includes 28,215,000 kg CO2e from Scope 1, 25,902,000 kg CO2e from Scope 2, and a significant 526,081,000 kg CO2e from Scope 3 emissions. This marks a commitment to transparency in their emissions reporting across all scopes. Ferring has set ambitious climate commitments, pledging to achieve net-zero greenhouse gas emissions by 2050. This commitment is aligned with the Science Based Targets initiative (SBTi) and was formalised in 2023. The company aims to implement strategies that encompass all scopes of emissions, reflecting a comprehensive approach to sustainability. Over the years, Ferring has demonstrated a trend of reducing its Scope 1 and 2 emissions, with a notable decrease from 33,982,000 kg CO2e in 2020 to 30,119,000 kg CO2e in 2021. This reduction showcases their ongoing efforts to improve energy efficiency and reduce their carbon footprint. Ferring's long-term strategy includes a focus on sustainable practices and innovation within the pharmaceutical sector, aiming to balance operational growth with environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - | - | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | - | - | - | - | - | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ferring is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
